NIST’s picture

By: NIST

I

n the age-old struggle between humans and microbes, bacteria seem to be regaining the offensive. Only about a dozen classes of chemicals protect us from the myriad pathogens that populate our environment. Numerous agencies have warned that evolved resistance could soon render common antibiotics useless, and that few replacement drugs are in the pipeline. But help may be on the way.

J.D. Power and Associates’s picture

By: J.D. Power and Associates

According to the recently released J.D. Power 2016 Member Health Plan Study, critical factors of health plan member satisfaction are highest in areas of the country that have more competition between different health plans.

NIST’s picture

By: NIST

Medical implants and spacecraft can suddenly go dead, often for the same reason: cracks in ceramic capacitors, which are devices that store electric charge in electronic circuits. These cracks, at first harmless and often hidden, can start conducting electricity, depleting batteries or shorting out the electronics.

ISO’s picture

By: ISO

With medical devices ranging from simple needles to life-saving high-tech implants, ensuring the highest possible level of safety is one of the industry’s greatest priorities. Here, as the chair of the ISO technical committee for quality management and related general aspects for medical devices, Eamonn Hoxey, Ph.D., shares his thoughts about the industry, its exponential growth, and why uniform and consistent standards are important.

James Brewton’s picture

By: James Brewton

The healthcare industry is under pressure to improve performance across strategic measures of performance, including delivery cost, operating revenue, employee engagement, patient safety, patient experience, and patient outcomes. A growing number of organizations turn to innovation as a way to survive and succeed in this new healthcare environment. Although many definitions exist for innovation, I like to define it as “the deliberate effort by an organization to find new ways for meeting business challenges.”

Katherine Watts’s picture

By: Katherine Watts

It amazes me how seemingly disparate ideas, when considered together, can create new ways of seeing the world. Bear with me for a minute, and I’ll share an insight I’ve received lately based on two seemingly unrelated ideas.

Stephen Ostroff’s picture

By: Stephen Ostroff

Since March 2015 it’s been my pleasure to serve as the Food and Drug Administration’s (FDA) Acting Commissioner. The FDA has broad responsibilities, and I’d like to share some important accomplishments during 2015.

Russ King’s picture

By: Russ King

As medical science has advanced, products submitted for FDA review are using increasingly complex formulations, including unique and creative combinations of drugs, biologics, and devices. Because of this complexity, combination products, by definition, may require intercenter consultations with the FDA.

Syndicate content